Long-Term Outcomes of Adding Ovarian Suppression to Tamoxifen in Premenopausal Women With HR+ Breast Cancer Who Remain Premenopausal or Resume Ovarian Function After Chemotherapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Adding Ovarian Suppression to Tamoxifen for Premenopausal Women With Hormone Receptor-Positive Breast Cancer After Chemotherapy: An 8-Year Follow-Up of the ASTRRA Trial
J. Clin. Oncol 2023 Aug 22;[EPub Ahead of Print], SY Baek, WC Noh, SH Ahn, HA Kim, JM Ryu, SI Kim, EG Lee, SA Im, Y Jung, MH Park, KH Park, SH Kang, J Jeong, E Park, SY Kim, MH Lee, LS Kim, W Lim, S Kim, HJ KimFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.